Cargando…
Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges
Essential thrombocythemia (ET) occurring with breast cancer is uncommon; the therapeutic approach varies and poses a challenge. A 65-year-old female presented to us after being diagnosed with hormone positive, HER2-negative infiltrating ductal carcinoma. She had a platelet count of 600 thou/cu mm. H...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109582/ https://www.ncbi.nlm.nih.gov/pubmed/30159181 http://dx.doi.org/10.1155/2018/2080185 |
_version_ | 1783350353803083776 |
---|---|
author | Seegobin, Karan Gharia, Bharatsinh Maharaj, Satish Zuberi, Lara |
author_facet | Seegobin, Karan Gharia, Bharatsinh Maharaj, Satish Zuberi, Lara |
author_sort | Seegobin, Karan |
collection | PubMed |
description | Essential thrombocythemia (ET) occurring with breast cancer is uncommon; the therapeutic approach varies and poses a challenge. A 65-year-old female presented to us after being diagnosed with hormone positive, HER2-negative infiltrating ductal carcinoma. She had a platelet count of 600 thou/cu mm. Her JAK2 mutation was positive. Bone marrow biopsy showed increased megakaryocytes. She was diagnosed with ET in the setting of breast cancer. She underwent breast conservation surgery after which aspirin was resumed. Anticipating thrombocytopenia during chemotherapy and given the absence of data combining hydroxyurea with standard chemotherapy used for breast cancer, we felt it prudent to delay cytoreductive therapy for her ET until after completion of breast cancer treatment. Her average platelet count during chemotherapy was 480 thou/cu mm with the lowest being 377 thou/cu mm. Her platelet count remained at goal between 300 and 350 thou/cu mm after four months of hydroxyurea. |
format | Online Article Text |
id | pubmed-6109582 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-61095822018-08-29 Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges Seegobin, Karan Gharia, Bharatsinh Maharaj, Satish Zuberi, Lara Case Rep Hematol Case Report Essential thrombocythemia (ET) occurring with breast cancer is uncommon; the therapeutic approach varies and poses a challenge. A 65-year-old female presented to us after being diagnosed with hormone positive, HER2-negative infiltrating ductal carcinoma. She had a platelet count of 600 thou/cu mm. Her JAK2 mutation was positive. Bone marrow biopsy showed increased megakaryocytes. She was diagnosed with ET in the setting of breast cancer. She underwent breast conservation surgery after which aspirin was resumed. Anticipating thrombocytopenia during chemotherapy and given the absence of data combining hydroxyurea with standard chemotherapy used for breast cancer, we felt it prudent to delay cytoreductive therapy for her ET until after completion of breast cancer treatment. Her average platelet count during chemotherapy was 480 thou/cu mm with the lowest being 377 thou/cu mm. Her platelet count remained at goal between 300 and 350 thou/cu mm after four months of hydroxyurea. Hindawi 2018-08-12 /pmc/articles/PMC6109582/ /pubmed/30159181 http://dx.doi.org/10.1155/2018/2080185 Text en Copyright © 2018 Karan Seegobin et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Seegobin, Karan Gharia, Bharatsinh Maharaj, Satish Zuberi, Lara Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges |
title | Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges |
title_full | Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges |
title_fullStr | Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges |
title_full_unstemmed | Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges |
title_short | Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges |
title_sort | coexistent breast cancer and essential thrombocythemia: how we addressed the therapeutic challenges |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109582/ https://www.ncbi.nlm.nih.gov/pubmed/30159181 http://dx.doi.org/10.1155/2018/2080185 |
work_keys_str_mv | AT seegobinkaran coexistentbreastcancerandessentialthrombocythemiahowweaddressedthetherapeuticchallenges AT ghariabharatsinh coexistentbreastcancerandessentialthrombocythemiahowweaddressedthetherapeuticchallenges AT maharajsatish coexistentbreastcancerandessentialthrombocythemiahowweaddressedthetherapeuticchallenges AT zuberilara coexistentbreastcancerandessentialthrombocythemiahowweaddressedthetherapeuticchallenges |